1	Investigating the marginal and herd effects of COVID-19 vaccination for reducing
2	case fatality rate: Evidence from the United States.
3	Tenglong Li ^{1*} , Zilong Wang ² , Shuyue He ¹ and Ying Chen ¹
4 5 6 7	 ¹ Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University ² Department of Financial and Actuarial Mathematics, Xi'an Jiaotong-Liverpool University * To whom correspondence may be addressed: <u>Tenglong.Li@xjtlu.edu.cn</u>
8	
9	Abstract
10	Vaccination campaigns have been rolled out in most countries to increase the vaccination
11	coverage and protect against case mortality during the ongoing pandemic. To evaluate the
12	effectiveness of COVID-19 vaccination, it is vital to disentangle the herd effect from the
13	marginal effect and parameterize them separately in a model. To demonstrate this, we
14	study the relationship between the COVID-19 vaccination coverage and case fatality rate
15	(CFR) based on a U.S. vaccination coverage at county level, with daily records from
16	March 11th, 2021 to Jan 26th, 2022 for 3109 U.S. counties. Using segmented regression,
17	we discovered three breakpoints of the vaccination coverage, at which the herd effects
18	could potentially exist. Controlling for county heterogeneity, we found the size of the
19	marginal effect was not constant but actually enlarged as the vaccination coverage
20	increased, and only the herd effect at the first breakpoint was statistically significant,
21	which implied indirect benefit of vaccination may exist at the early stage of a vaccination
22	campaign. Our results have demonstrated that public health researchers should carefully
23	differentiate and quantify the herd and marginal effects in analyzing vaccination data, to
24	better inform vaccination campaign strategies as well as evaluate vaccination
25	effectiveness.

Keywords: COVID-19 vaccine, herd effect, marginal effect, case fatality rate, segmented
 regression.

28 1 Introduction

29 The world has been living in the tunnel of COVID-19 pandemic since the outbreak in

30 2019, yet without a clear idea about its outlet. A great hope has been placed in COVID-

31 19 vaccines to end the pandemic, as clinical trial results suggested COVID-19

32 vaccination can effectively prevent symptomatic infections especially severe symptoms,

33 which protects against mortality associated with infections [1-3]. For this reason, public

34 demand for COVID-19 vaccines was fervent and vaccination campaigns were initiated all

35 over the world, for an early safe vaccine supply for populations at risk as well as a

36 massive vaccine supply to match the public's demand [4-5]. For an example, the Food

37 and Drug Administration (FDA) issued emergency use authorizations (EUA) for Pfizer-

38 BioNTech and Moderna COVID-19 vaccines in December 2020, which marked the

39 beginning of the vaccination campaign in the U.S. COVID-19 vaccines were then first

40 allocated for populations at risk, the elderly population (age 65+) and the frontline

41 (mostly healthcare and education) workers. After president Biden announced that all

42 Americans would be eligible for COVID-19 vaccines by May 1st, 2021, the vaccination

43 campaign was further accelerated [6]. Booster doses of COVID-19 vaccines were

44 introduced to restore the level of protection (antibody) eroded by time [7-9]. By

45 November 24, 2022, more than 80% of Americans have received at least one dose and

46 more than 68% of Americans have completed a primary series of COVID-19 vaccine

47 [10]. Literature has reported that the vaccination coverage is negatively associated with

48 case fatality rate (CFR), which refers to the mortality rate among those who are infected
49 (i.e., confirmed COVID cases) [11-12].

50 It is necessary to decompose the protection effect of COVID-19 vaccines in order to 51 better understand the underlying mechanism [13]. The protection effect of COVID-19 52 vaccines is in general a mix of two different effects, i.e., the direct effect and the indirect 53 effect [14]. The direct effect refers to direct protection of inoculated individuals, as the 54 vaccines can effectively reduce individual susceptibility to COVID-19 infection and 55 severe symptoms [13-14]. The indirect effect, however, is a bit abstract and attributed to 56 herd immunity, which is a conception states that transmission of the agent can be largely 57 prevented if a fixed proportion of the population is immunized (either by vaccination or 58 by recovery from infection; this proportion is called herd immunity threshold), rendering 59 an infectious disease insignificantly dangerous for public health [15-16]. The indirect 60 effect is defined as the protection gained by unvaccinated people, through the reduced 61 number of infected people in the population as well as their reduced infectiousness, 62 which can be achieved by vaccinating certain proportions of the population [13]. It 63 should be noted here that those proportions we mentioned above are different from herd 64 immunity threshold as they potentially correspond to different levels of herd immunity in 65 a population [17]. In fact, those proportions are thresholds for triggering the indirect 66 effect (with different sizes) in the course of a vaccination campaign for a target 67 population. 68 The above concepts of the direct and indirect effects should be contextualized in the 69 investigation of the impact of COVID-19 vaccination on case fatality rate (CFR). The

70 direct effect could be interpreted as the reduction in CFR associated with one unit/percent

71 increase in the vaccination coverage, i.e., the direct effect evaluates the marginal gain 72 during a vaccination campaign. For this reason, the direct effect is referred to as the 73 marginal effect in this paper. The indirect effect could be interpreted as the additional 74 reduction in CFR if the vaccination coverage passes certain unknown thresholds, i.e., the 75 indirect effect quantifies the additional gain potentially due to herd immunity in the 76 process of vaccinating a target population. To better characterize its nature, the indirect 77 effect is referred to as the herd effect in this paper. It's particularly important to 78 disentangle the herd effect from the marginal effect, for the following three reasons: First, 79 the marginal and herd effects address different scientific questions with regard to distinct 80 groups of people (i.e., the vaccinated individuals versus the unvaccinated individuals). 81 Second, as discussed earlier, there are underlying thresholds for triggering the herd 82 effects, and those thresholds essentially delineate different stages in a vaccination 83 campaign where the marginal and herd effects may not be constant across those stages. 84 Third, given the aforementioned two reasons, a deeper knowledge about the protection 85 effect of vaccination is likely gained by learning the marginal and herd effects, and 86 vaccination strategies could be optimized for a target population based on such 87 knowledge. Unfortunately, we haven't seen research on this important topic so far. 88 Our goal in this paper is to estimate the herd and marginal effects based on a dataset from 89 the U.S. Centers for Disease Control and Prevention (CDC), which records various 90 vaccination coverages for each U.S. county daily [10]. We hypothesize that both the herd 91 and marginal effects exist and are significantly negative for modeling CFR. The 92 segmented regression is employed first to identify the breakpoints which are considered 93 as the thresholds for triggering the herd effect, based on data of all the U.S. counties

94 included in our study. With the identified breakpoints, we estimate the herd and marginal

95 effects at national level using segmented regression and at county level using mixed

96 model. Data on social vulnerability index (SVI) for individual counties is also included to

97 control for health disparities due to sociodemographic factors at county level [18].

98 Heterogeneity among individual counties is further evaluated by the random effects

99 associated with the herd and marginal effects among in a mixed model.

100 This paper is structured as follows: In the next section of materials and methods, the data

101 used in this paper will be described in details, along with the models adopted for analyses

102 at both national level and county level. The results from our analyses at national level and

103 county level are presented and explained in the section of results, with a focus on the

104 estimation and interpretation of the herd and marginal effects of vaccination regarding

105 CFR. Our findings will be summarized in the discussion section, where important

106 implications and limitations of our study will also be discussed.

107 2 Materials and Methods

108 **2.1 Data**

109 Our data comes from three different sources. The US vaccine administration and equity

110 dataset is obtained from the CDC website and has vaccination coverages of the general

111 population and its subpopulations (defined by age) recorded daily at county level [10].

112 The percent of people who completed a primary series of vaccination in the general

113 population was extracted from the dataset and served as the main covariate in our model.

114 The daily CFR at county level was calculated as the ratio between the daily count of

deaths and the daily count of COVID-19 cases, based on the time series summary tables

116 of COVID-19 deaths and confirmed cases, which were accessed from the COVID-19

117	data repository by the Center for Systems Science and Engineering (CSSE) at John
118	Hopkins University [19]. To further control for county heterogeneity, we used a dataset
119	from the Centers for Disease Control and Prevention Social Vulnerability Index (CDC
120	SVI) database, created by the Geospatial research, Analysis & Services Program under
121	the Agency for Toxic Substances and Disease Registry [18]. The CDC SVI database was
122	established to help health officials and emergency response planners identify counties
123	that will most likely need support before, during, and after a hazardous event. CDC SVI
124	ranks counties on 15 social factors and further groups them into four themes, namely
125	socioeconomic status, household composition & disability, minority status & language,
126	and housing type & transportation [20]. We chose to use the theme-specific ranking
127	which was constructed by summing the percentiles of the factors under each theme. The
128	theme-specific ranking was set in the range from 0 to 1, with higher values indicating
129	greater vulnerability.
130	The vaccination coverages and daily CFR for the period between March 11th, 2021 and
131	Jan 26th, 2022 were selected. We chose March 11th, 2021 as it was the date when
132	president Biden announced that COVID-19 vaccine would be available for all American
133	adults by May 1st, 2021, an event marked the beginning of massive vaccination campaign
134	in the U.S. We chose Jan 26 th , 2022 as the ending date of our study as it was reported on
135	this date that Omicron variant accounted for 99.9% of the new infections. This would
136	alleviate the concern of potential confounding effect of Omicron variant regarding the
137	relationship between the vaccination coverage and CFR. 31 counties with missing values
138	on county FIPS code, vaccination coverages, the CDC SVI or CFR were excluded, and
139	the final dataset has 1001098 observations clustered by 3109 U.S. counties. To prepare

140 the dataset for analysis at national level, we further extracted the average CFR and

141 average vaccination coverage (i.e., the percent of people who completed a primary series

142 of COVID-19 vaccine) across all the counties in our dataset for each day during our study

143 period.

144 **2.2 Models**

145 Segmented regression models were employed to estimate the herd and marginal effects.

146 Segmented regression is very similar to ordinary regression, with the only difference that

147 regression coefficients should be estimated repeatedly for different local regions whose

boundaries are defined by breakpoints, which represent the thresholds of structural

149 changes in regression models [21-22]. Typically, the first step is to determine the number

150 of breakpoints, which can be achieved by a model selection alike procedure, i.e., models

151 with different number of breakpoints are compared in terms of their model fit indices

152 (such as AIC or BIC) to determine the optimized number of breakpoints. The second step

153 is to estimate the locations of breakpoints given the number of breakpoints. The third

step, based on the estimated breakpoints, is then to fit regression models to different local

regions separated by the breakpoints. Normally, one would expect all regression

156 coefficients to be changeable across different regions, unless otherwise specified.

157 For our analysis at national level, we intend to examine the relationship between CFR

and the vaccination coverage, based on the dataset comprising only the average

159 vaccination coverage and CFR in the U.S. The following regression model is formulated

160 for the analysis at national level:

$$y_{t} = \beta_{0} + \beta_{1}X_{t} + \sum_{k=1}^{m} \alpha_{k} I_{\{X_{t} \in \Psi_{k}\}} + \sum_{k=1}^{m} \delta_{k} X_{t} I_{\{X_{t} \in \Psi_{k}\}} + \varepsilon_{t}$$
(1)

161 where y_t and X_t denote the average CFR and vaccinate coverage in the U.S on day t. The 162 model (1) is built on the estimated breakpoints $b_1 < b_2 < \cdots < b_m$, which implies there 163 are m + 1 different local regions and m different breakpoints in total (except b_0 and 164 b_{m+1} which are the minimum and maximum of X_t). The local regions separated by the 165 breakpoints are denoted by $\Psi_k = [b_k, b_{k+1})$ for $k = 1, 2, \dots, m$. The reference local 166 region Ψ_0 , although omitted from the model (1), refers to the local region $\Psi_0 = [b_0, b_1)$. 167 The indicator function $I_{\{X_t \in \Psi_k\}}$ creates the dummy variable which assigns value 1 if the value of X_t falls in the local region Ψ_k and 0 otherwise, which operationally divides the 168 169 range of X_t into the local regions. The marginal effects in those local regions are 170 characterized by β_1 for the reference region and $\beta_1 + \delta_k$ for the local region Ψ_k , and 171 these parameters quantify the marginal gain/drop in CFR if the vaccination coverage 172 increases by one percent. The herd effects for the local region Ψ_k relative to its previous 173 region are characterized by $\alpha_k - \alpha_{k-1}$ (for Ψ_1 it is just α_1), as α_k quantifies the additional gain/drop in CFR if the vaccination coverage passes the threshold b_k , 174 175 compared to the intercept term β_0 in the reference region Ψ_0 . The breakpoints $b_k k = 1, 2, \dots, m$, are estimated based on the model (1) and the dataset 176 177 for the analysis at national level (i.e., with only average daily CFR and vaccination rate in 178 the U.S.). Naturally, they reflect the structural changes in the relationship between CFR 179 and the vaccination coverage in general, and they can be applied to the analysis at county 180 level where we use the longitudinal data (322 days) for all the counties (3109 counties), 181 along with the CDC SVI indicators for explaining county heterogeneity. We build the 182 following mixed model for the analysis at county level:

$$y_{it} = \beta_0 + \beta_1 X_{it} + \sum_{k=1}^m \alpha_k I_{\{X_{it} \in \Psi_m\}} + \sum_{k=1}^m \delta_k X_{it} I_{\{X_{it} \in \Psi_m\}} + \gamma Z_i + u_1 X_{it} + u_0$$

$$+ \sum_{k=1}^m \widetilde{\alpha}_k I_{\{X_{it} \in \Psi_m\}} + \sum_{k=1}^m \widetilde{\delta}_k X_{it} I_{\{X_{it} \in \Psi_m\}} + \varepsilon_{it}$$
(2)

where y_{it} and X_{it} denote the CFR and vaccination coverage for county *i* at day *t*. Z_i is the 183 184 covariate vector that contains CDC SVI theme-specific rankings on the four main themes 185 for county *i*. β_0 , β_1 , α_k , δ_k are the parameters characterize the herd and marginal effects, 186 as similarly defined in the model (1), except in the model (2) they are fixed effects. 187 Correspondingly, we have their random effects characterized by $u_0, u_1, \tilde{\alpha}_k, \tilde{\delta}_k$ that are 188 due to the heterogeneity among the counties that cannot be explained away by the fixed 189 effects of county rankings on CDC SVI, which are represented by γ . The Model (2) is 190 built on the same set of breakpoints b_k , $k = 1, 2, \dots, m$, that are obtained based on the

191 model (1) and the dataset for the analysis at national level. This means the model (2)

shares the same local regions $\Psi_k = [b_k, b_{k+1})$ for $k = 1, 2, \dots, m$, across all the counties

193 in our study. The significances of the fixed effects β_{0i} , β_{1i} , α_k , δ_k as well as their

194 corresponding random effects $u_0, u_1, \tilde{\alpha}_k, \tilde{\delta}_k$ will be checked via model outputs and

195 comparison tests.

196 **3 Results**

3.1 The results of the analysis at national level

As mentioned above, the dataset used for the analysis at national level has two variables,
i.e., average daily CFR and average vaccination coverage in the U.S.. The breakpoints
were estimated based on this dataset using the "segmented" package in R (version 4.2.0)
[22]. To avoid overfitting, we set the maximum number of the breakpoints as 3, based on

202 the curve between the average daily CFR and the average daily vaccination coverage 203 depicted in Figure 1. The segmented package then does an automatic selection of the 204 number of breakpoints based on BIC, and it estimated the locations of the breakpoints 205 conditional on the optimized number of the breakpoints. The estimated breakpoints were 206 superimposed on the curve in Figure 1, to further validate those estimates align with the 207 observed structural changes. 208 The breakpoints were estimated as 32%, 36% and 47%, which suggested that the herd 209 effect of vaccination may be associated with the thresholds of 32%, 36% and 47% in the 210 vaccination coverage. Based on those breakpoints, we have four different local regions, 211 namely $\Psi_1 = [8.66\%, 32\%); \Psi_2 = [32\%, 36\%); \Psi_3 = [36\%, 47\%); \Psi_4 =$ 212 [47%, 49.28%), with the minimum and maximum of the average daily vaccination 213 coverages as 8.66% and 49.28% respectively. Table 1 lists the estimates of the regression 214 coefficients based on the model (1). We further calculated the herd and marginal effect 215 estimates which are tabulated in Table 2. The marginal effect in the first local region Ψ_1 216 was insignificant, which suggested that the drop in the CFR per percent increase in the 217 vaccination coverage was not significantly different from 0, if the vaccination coverage 218 did not surpass 32%. The herd effect at the threshold 32% was also insignificant, which 219 was largely due to the insignificant marginal effect in the region Ψ_1 . We found a 220 significant marginal effect in the second local region Ψ_2 (-0.057), which indicated that 221 there was a drop of 0.057 percent in the CFR for every percent increase in the vaccination 222 coverage in this region, evidencing that the protection effect of COVID vaccination 223 against mortality. In addition, the herd effect at the threshold 36% was significant too (-224 (0.233), suggesting that there was a further drop of (0.233) percent in the CFR besides the



- local region Ψ_3 , however, we observed a slight positive marginal effect in the CFR
- 227 (0.003), which means the marginal gain of vaccination (in terms of the reduction in CFR)
- 228 disappeared and vaccination was somehow harmful for protecting against mortality.
- 229 Correspondingly, the herd effect at the threshold 47% was also positively significant
- 230 (0.009), suggesting again that vaccination was not helpful at this stage. The marginal
- effect in the fourth local region Ψ_4 was strongly negative, specifically there was a drop of
- 232 0.115 percent in the CFR associated with every percent increase in the vaccination



coverage at this stage.



Figure 1. The relationship between the average vaccination coverage and the average

CFR in the U.S. The solid dots represent the breakpoints estimated by the "segmented"package in R.

Parameter	Estimate	T Ratio	p-value
β ₀	1.976	624.70	<0.001
β_1	0.000	0.28	0.78
α1	-0.003	-0.90	0.37
δ_1	-0.057	-45.32	<0.001
α2	-0.236	-80.67	<0.001
δ_2	0.003	7.50	<0.001
α ₃	-0.227	-55.09	<0.001
δ_3	-0.115	-47.03	<0.001

	239	Table 1.	The	regression	model	parameter	estimates	for	the a	nalysis	at national	level.
--	-----	----------	-----	------------	-------	-----------	-----------	-----	-------	---------	-------------	--------

240

Table 2. The herd and marginal effect estimates for the analysis at national level.

Effect Location		Estimate	p-value
1 st Marginal Effect	$\Psi_1 = [8.66\%, 32\%)$	0.000	0.78
1 st Herd Effect	<i>b</i> ₁ = 32%	-0.003	0.37
2 nd Marginal Effect	Ψ ₂ = [32%, 36%)	-0.057	<0.001
2 nd Herd Effect	$b_2 = 36\%$	-0.233	<0.001
3 rd Marginal Effect	Ψ ₃ = [36%, 47%)	0.003	<0.001
3 rd Herd Effect	<i>b</i> ₃ = 47%	0.009	0.02
4 th Marginal Effect	$\Psi_4 = [47\%, 49.28\%)$	-0.115	<0.001

3.2 The results of the analysis at county level

244 We further investigated the marginal and herd effects of COVID vaccination based on an 245 analysis at county level, where the daily CFR and vaccination coverages from March 246 11th, 2021 to Jan 26th, 2022 as well as the CDC SVI rankings for 3109 U.S. counties were 247 used. The estimated breakpoints of 32%, 36% and 47%, obtained based on the analysis at 248 national level, were adopted for our analysis at county level. The mixed model (2) was 249 employed to account for the clustered data at county level, and its fixed and random 250 effect estimates are tabulated in the Table 3. Furthermore, the estimates of herd and 251 marginal effects, as well as their corresponding random effect estimates, are listed in the 252 Table 4. To determine the significance of the random effects, we compared the full model 253 (i.e., the model (2)) with two different reduced models (one without the random effects 254 associated with all the marginal effects, i.e., $u_1, \tilde{\delta}_1, \tilde{\delta}_2, \tilde{\delta}_3$; another one without the 255 random effect associated with the first marginal effect only, i.e., u_1), and the resultant 256 tests gave p-values smaller than 0.001, suggesting that it was necessary to include 257 random effects for all the marginal and herd effect parameters. 258 Across all the U.S. counties in our data, the marginal effect was significantly negative in 259 the first local region Ψ_1 (i.e., when the vaccination coverage was between 8.66% and 260 32%), specifically one percent increase in the vaccination coverage was associated with 261 0.004 percent drop in the CFR. The first herd effect at the threshold of 32% was -0.025 262 and significant, meaning there was an additional drop of 0.025 percent in the CFR as the 263 vaccination coverage reached 32%, beyond the marginal effect observed in Ψ_1 . The 264 marginal effect in the second local region Ψ_2 was also significantly negative (-0.01), 265 which showed that there was 0.01 percent drop in the CFR per one percent increase in the

266 vaccination coverage, when the vaccination coverage was between 32% and 36%. The 267 second herd effect, however, was overall insignificant, which suggested additional 268 protection effect at the threshold 36% may not exist. Similarly, we found significant 269 marginal effect (-0.023) for the third local region Ψ_3 but insignificant herd effect at the threshold 47%. The marginal effect within the fourth local region Ψ_4 was the strongest, 270 271 as every percent increase in the vaccination coverage was associated with 0.043 percent 272 reduction in the CFR, if the vaccination coverage surpassed 47%. 273 Furthermore, heterogeneity among the U.S. counties regarding the herd and marginal 274 effect estimates was evident. For the first herd effect (at 32%), the fixed effect estimate 275 was -0.025 with a random effect of 0.024, and this means roughly 56% of the counties 276 had negative herd effects as expected, but the other 44% of the counties could have no 277 herd effect or even positive herd effects at the threshold 32%. For the second and third 278 herd effect (at 36% and 47% respectively), roughly 49% of the counties have negative 279 herd effects, which further demonstrated that those two herd effects were not significant 280 among the counties. Regarding the marginal effects: although their fixed effect estimates 281 were all very significant (p-value < 0.001), their random effect estimates suggested the 282 fourth marginal effect was the strongest one (was negative in 73% of the counties). The 283 first, second and third marginal effects were negative in approximately 57%, 54% and 284 62% of the U.S. counties. All taken, the protection effect of COVID vaccination was 285 confirmed in general and for the majority of the U.S. counties, while substantial 286 heterogeneity that defined the size and the validity of the protection effect for individual 287 county still existed. We also found that only one CDC SVI theme ranking, i.e., rankings 288 on household composition & disability, could help explain the county heterogeneity.

- 289 Unsurprisingly, this CDC SVI theme ranking was positively related to CFR, and
- specifically one percentile rise in the theme ranking could result in 0.8 percent increase in
- 291 CFR.
- 292

293 Table 3. The mixed model parameter estimates pertaining to fixed effects (F.E.) and

random effects (R.E.) for the analysis at county level. The standard errors (S.E.) of the random effects (R.E.) are also provided.

Parameter	F.E. Est	F.E. T Ratio	F.E. p-value	R.E. Est	S.E. of R.E.
β_0	1.64	28.88	< 0.001	1.33	0.03
β_1	-0.004	-8.85	<0.001	0.0005	0.00001
α1	-0.025	-7.35	< 0.001	0.024	0.0008
δ_1	-0.007	-3.74	< 0.001	0.007	0.0002
α2	-0.018	-2.84	0.005	0.091	0.003
δ_2	-0.02	-13.07	<0.001	0.006	0.0002
α ₃	-0.004	-0.35	0.728	0.2	0.007
δ_3	-0.039	-23.49	< 0.001	0.004	0.0002
γ_1	0.0004	0.33	0.744	n/a	n/a
γ_2	0.807	11.00	<0.001	n/a	n/a
γ_3	-0.057	-0.73	0.467	n/a	n/a
γ_4	0.004	0.05	0.961	n/a	n/a

296

297

298

299

- 301 Table 4. The herd and marginal effect estimates for the analysis at county level. The fixed
- 302 effect estimates (F.E. Est), the random effect estimates (R.E. Est) as well as the p-value
- 303 for the F.E Est are provided.

Effect	Location	F.E. Est	F.E. p-value	R.E. Est
1 st Marginal Effect	$\Psi_1 = [8.66\%, 32\%)$	-0.004	<0.001	0.0005
1 st Herd Effect	<i>b</i> ₁ = 32%	-0.025	<0.001	0.024
2 nd Marginal Effect	$\Psi_2 = [32\%, 36\%)$	-0.01	<0.001	0.008
2 nd Herd Effect	$b_2 = 36\%$	0.008	0.70	0.115
3 rd Marginal Effect	$\Psi_3 = [36\%, 47\%)$	-0.023	<0.001	0.006
3 rd Herd Effect	$b_3 = 47\%$	0.014	0.545	0.29
4 th Marginal Effect	$\Psi_4 = [47\%, 49.3\%)$	-0.043	<0.001	0.005

304

305 4 Discussion

306 Vaccination has been acknowledged as an effective tool to reduce hospitalization and 307 mortality related to COVID-19 infections, and vaccination campaign has been rolled out 308 in virtually every country that has access to COVID-19 vaccines. Understanding the 309 effect of COVID-19 vaccination in terms of case fatality rate (CFR) reduction has 310 unquestionably profound meaning, for a successful implementation of the COVID-19 311 vaccination campaign. Drawing on the direct and indirect effects of vaccination from 312 literature, we rename the direct effect as the marginal effect of vaccination and the 313 indirect effect as the herd effect of vaccination, to better describe the nature of those 314 effects in terms of reducing the CFR. Defining the herd and marginal effects also helps 315 build regression models for obtaining their estimates, as those two kinds of effects require 316 different parameterization in the model. Analysis at the national level and county level

317	for the United States, were then implemented based on datasets containing the daily
318	vaccination coverages and case reports in the U.S. Theme rankings for individual
319	counties from the CDC SVI were also included to explain heterogeneity at county level.
320	Our analysis at national level suggested three different locations (i.e., when the
321	vaccination rate reached 32%, 36% and 47%) for possible herd effects and strong
322	significance for the marginal effects, which was further confirmed by our analysis at
323	county level after controlling for county heterogeneity.
324	Our analyses have demonstrated how COVID-19 vaccination protects against COVID
325	related mortality over the course of COVID-19 vaccination campaign in the U.S. In
326	general, COVID-19 vaccination indeed can significantly reduce the CFR, but its effect is
327	not constant during the vaccination campaign. The estimated breakpoints have divided
328	the vaccination campaign into four different regions based on the vaccination coverage,
329	i.e., $\Psi_1 = [8.66\%, 32\%), \Psi_2 = [32\%, 36\%), \Psi_3 = [36\%, 47\%)$ and $\Psi_4 =$
330	[47%, 49.3%). The marginal effects in those four regions are correspondingly -0.004, -
331	0.01, -0.023 and -0.043, which are all significant. This shows the vaccination can directly
332	result in meaningful reduction in the CFR and thus it should be recommended especially
333	for the unvaccinated population, as the marginal effects largely quantify the reduced risks
334	of mortality that one would benefit from the vaccination if he/she chooses to get
335	vaccinated. We also observe that the sizes of the marginal effects enlarge as the
336	vaccination coverages increases, which suggests that the direct benefit of COVID-19
337	vaccination is becoming more and more significant as the vaccination coverage in the
338	population increases. Our results also indicate the existence of herd effect, specifically at
339	the threshold 32%. The herd effect at the threshold 32% is statistically significant (-

340	0.025), which demonstrates the indirect (additional) benefit brought by the vaccination
341	once the vaccination coverage reaches 32% in the population. This implies that one
342	would indirectly benefit from the COVID-19 vaccination even if he/she is not vaccinated
343	as long as the vaccination coverage passes 32%, by a 0.025% reduction in the CFR.
344	Our results have important implications for the COVID-19 vaccination strategies. First,
345	our findings suggest that vaccination campaign should be rapidly carried out at the initial
346	stage, to trigger the threshold for herd effects, in order to procure additional protection of
347	COVID-19 vaccination against the CFR for the entire population regardless of individual
348	vaccination statuses. This echoes our earlier finding of the significant herd effect at the
349	first breakpoint 32% and is consistent with recommendations offered by the literature
350	[3,4,23,24,25]. It is noteworthy that, a rapid effective implementation at the initial stage
351	can pose considerable logistical challenges for a vaccination campaign [23,26,27].
352	Therefore, careful resource planning is required for the access, transportation, storage and
353	distribution of vaccines, which has been exemplified by the vaccination campaign in the
354	U.S. [25,28]. Second, eligible unvaccinated individuals should be encouraged (even
355	urged) to get vaccinated at all stages of a vaccination campaign, as the marginal effects
356	were evident across all the local regions defined for the U.S. vaccination campaign in our
357	analysis. More profoundly, we found the whole population would benefit more if more
358	people got vaccinated, as the size of marginal effect was positively correlated with the
359	vaccination coverage in the population. The gain from the marginal effects, on average,
360	also outweighed the gain from the herd effects, as manifested by the Table 4. These key
361	observations suggest that the marginal effect is more important than the herd effect for
362	the protection against COVID mortality [15]. Thus, vaccination strategy should focus on

363 how to capitalize on the marginal effect, i.e., promote individual vaccination willingness

and accessibility, in order to continuously push for a higher vaccination rate in the

365 population [15,29]. Based on our results, the goal of a vaccination campaign should be

366 pursuing a higher vaccination coverage in the population, rather than meeting a

367 predefined threshold for triggering the herd effect [4,29,30].

368 Heterogeneity among the U.S. counties in terms of the marginal and herd effects is

369 considerable. The sizes and even the signs of the marginal and herd effects could vary

across all the counties, which signals that the protection effect of COVID-19 vaccination

is not constant and partially determined by county idiosyncrasy. For example, we took

372 the social vulnerability index (SVI) into account in our analysis and did find the theme of

373 household composition & disability significantly was significantly associated with the

374 CFR after controlling for the vaccination coverage. This indicates that demographical

375 features of individual county, such as the age distribution and disability proportion, play

376 vital roles in explaining the heterogeneity existed for the relationship between the

377 vaccination coverage and the CFR [31]. Although the other three SVI themes, namely

378 socioeconomic status, minority status & language and housing type & transportation,

379 were not statistically significant, factors such as environmental conditions [32], political

atmosphere [33] and non-pharmaceutical interventions [34] could contribute to county

381 heterogeneity, and potentially confound the relationship between the vaccination

382 coverage and the CFR. Most notably, research has shown that vaccine hesitancy

383 (willingness) is a key determinant of vaccination coverage, and it potentially mediates the

relationship between the factors influencing the CFR (like SVI) and the CFR itself, and

385 therefore variation of vaccine hesitancy among the U.S. counties potentially accounts for 386 a significant portion of the county heterogeneity observed in our paper [35-36]. 387 There are limitations in our analysis: We did not investigate the impact of COVID-19 388 variants on the CFR and the vaccine effectiveness, considering there were different 389 COVID-19 variants (and their lineages and sublineages), such as alpha, delta and 390 omicron, spreading during our study period, as we can hardly identify the boundaries of 391 the spreading period of each variant from the data. For the similar reason, the potential 392 impact of different brands of vaccines (such as BioNTech and Moderna) was also not 393 considered in our model, as the data did not contain information about the number of 394 administered doses of every specific brand. Most importantly, our model treats the 395 breakpoints as the fixed values across all the counties, which may not be true as the 396 breakpoints could vary across different counties as a result of unique evolvement of 397 vaccination campaign in individual counties. Unfortunately, allowing each county to have 398 its own breakpoints would require a huge number of parameters and a complex Bayesian 399 model, which goes beyond the scope of this paper [37]. Therefore, further robustness and 400 sensitivity analyses may be warranted [38-41]. 401 To summarize, we have shown the existence of the herd effects via a segmented 402 regression model. Specifically, we identified three different breakpoints that represented 403 the locations of the herd effects. Accounting for county heterogeneity, we found one of 404 the three herd effects to be statistically significant, and it suggested that additional 405 indirect benefit of COVID-19 vaccination may exist at the earlier stage of a vaccination 406 campaign. We also found the marginal effect size varied at different stages of the 407 vaccination campaign, and specifically the marginal (direct) benefit of COVID-19

408	vaccination likely	y became larg	er as the	e vaccination	coverage increa	used. Our findings
-----	--------------------	---------------	-----------	---------------	-----------------	--------------------

- 409 demonstrate that the herd and marginal effects should be carefully differentiated and
- 410 assessed in analyzing vaccination data, to better inform vaccination campaign strategies
- 411 as well as evaluate vaccination effectiveness.

- ----

431 References [1] Dal-Ré R, Bekker LG, Gluud C, et al. Ongoing and future COVID-19 vaccine clinical 432 433 trials: challenges and opportunities. Lancet Infect Dis. 2021;21(11):e342-e347. 434 doi:10.1016/S1473-3099(21)00263-2 435 436 [2] Yan ZP, Yang M, Lai CL. COVID-19 vaccines: A review of the safety and efficacy 437 of current clinical trials. Pharmaceuticals (Basel). 2021;14(5). doi:10.3390/ph14050406 438 439 [3] Ahmed S, Khan S, Imran I, et al. Vaccine development against COVID-19: Study 440 from pre-clinical phases to clinical trials and global use. Vaccines (Basel). 2021;9(8):836. 441 doi:10.3390/vaccines9080836 442 443 [4] World Health Organization. *Global Covid-19 Vaccination Strategy in a Changing* 444 World.; 2022. https://www.who.int/publications/m/item/global-covid-19-vaccination-445 strategy-in-a-changing-world--july-2022-update 446 447 [5] Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 448 vaccinations. Nat Hum Behav. 2021;5(7):947-953. doi:10.1038/s41562-021-01122-8 449 450 [6] Hodge JG. Nationalizing public health emergency legal responses. J Law Med Ethics. 451 2021;49(2):315-320. doi:10.1017/jme.2021.45 452 453 [7] Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster 454 against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. 455 doi:10.1056/NEJMoa2114255 456 457 [8] Mahase E. Covid-19 booster vaccines: What we know and who's doing what. BMJ. 458 2021;374:n2082. doi:10.1136/bmj.n2082 459 460 [9] Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 booster vaccines 461 against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 462 2022;28(4):831-837. doi:10.1038/s41591-022-01699-1 463 464 [10] Centers for Disease Control and Prevention. COVID Data Tracker. Accessed 465 November 24, 2022. https://covid.cdc.gov/covid-data-tracker. 466 467 [11] Zhao S, Lou J, Cao L, et al. Differences in the case fatality risks associated with 468 SARS-CoV-2 Delta and non-Delta variants in relation to vaccine coverage: An early 469 ecological study in the United Kingdom. Infect Genet Evol. 2022;97(105162):105162. 470 doi:10.1016/j.meegid.2021.105162 471 472 [12] Lee YC, Chang KY, Mirsaeidi M. Association of COVID-19 case-fatality rate with 473 state health disparity in the United States. Front Med (Lausanne). 2022;9:853059. 474 doi:10.3389/fmed.2022.853059 475

476 477 478	[13] Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. <i>Science</i>.2020;370(6518):763-765. doi:10.1126/science.abe5938
479 480 481 482	[14] Halloran ME, Haber M, Longini IM Jr, Struchiner CJ. Direct and indirect effects in vaccine efficacy and effectiveness. <i>Am J Epidemiol</i> . 1991;133(4):323-331. doi:10.1093/oxfordjournals.aje.a115884
483 484 485	[15] Morens DM, Folkers GK, Fauci AS. The concept of classical herd immunity may not apply to COVID-19. <i>J Infect Dis</i> . 2022;226(2):195-198. doi:10.1093/infdis/jiac109
486 487 488	[16] Randolph HE, Barreiro LB. Herd immunity: Understanding COVID-19. <i>Immunity</i>. 2020;52(5):737-741. doi:10.1016/j.immuni.2020.04.012
489 490 491	 [17] Gallagher ME, Sieben AJ, Nelson KN, et al. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates. <i>Nat Med.</i> 2021;27(1):4-5. doi:10.1038/s41591-020-01172-x
492 493 494 495	[18] Flanagan BE, Hallisey EJ, Adams E, Lavery A. Measuring community vulnerability to natural and anthropogenic hazards: The centers for disease control and prevention's social vulnerability index. <i>J Environ Health</i> . 2018;80(10):34-36.
496 497 498 499	[19] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. <i>Lancet Infect Dis.</i> 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1
500 501 502 503 504	[20] Place and Health, Agency for Toxic Substances and Disease Registry. <i>CDC SVI</i> 2018 Documentation.; 2020. Accessed June 7, 2022. https://www.atsdr.cdc.gov/placeandhealth/svi/documentation/SVI_documentation_2018. html.
505 506 507	[21] Muggeo VMR. Estimating regression models with unknown breakpoints. <i>Stat Med</i> . 2003;22(19):3055-3071. doi:10.1002/sim.1545
507 508 509 510	[22] Muggeo VMR. Segmented: an R package to fit regression models with broken-line relationships. <i>R news</i> . 2008;8(1):20-25.
511 512 513	[23] McKee M, Rajan S. What can we learn from Israel's rapid roll out of COVID 19 vaccination? <i>Isr J Health Policy Res</i> . 2021;10(5):1-4.
514 515 516	[24] Sah P, Vilches TN, Moghadas SM, et al. Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. <i>EClinicalMedicine</i>. 2021;35(100865):100865. doi:10.1016/j.eclinm.2021.100865
517 518 519 520 521	[25] Moghadas SM, Sah P, Fitzpatrick MC, et al. COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United States. <i>bioRxiv</i> . Published online 2021. doi:10.1101/2021.07.07.21260156

522 523 524 525	[26] Aguilera X, Mundt AP, Araos R, Weitzel T. The story behind Chile's rapid rollout of COVID-19 vaccination. <i>Travel Med Infect Dis</i> . 2021;42(102092):102092. doi:10.1016/j.tmaid.2021.102092
526 527 528	[27] Glied S. Strategy drives implementation: COVID vaccination in Israel. <i>Isr J Health Policy Res.</i> 2021;10(1):9. doi:10.1186/s13584-021-00445-1
529	[28] Vilches TN, Moghadas SM, Sah P, et al. Estimating COVID-19 infections.
530	hospitalizations, and deaths following the US vaccination campaigns during the
531	pandemic. JAMA Netw Open. 2022;5(1):e2142725.
532	doi:10.1001/jamanetworkopen.2021.42725
533	5 1
534	[29] Monge S, Olmedo C, Alejos B, et al. Direct and indirect effectiveness of mRNA
535	vaccination against severe acute respiratory syndrome Coronavirus 2 in long-term care
536 537	facilities, Spain. Emerg Infect Dis. 2021;27(10):2595-2603. doi:10.3201/eid2710.211184
538	[30] Clemente-Suárez VJ, Hormeño-Holgado A, Jiménez M, et al. Dynamics of
539	population immunity due to the herd effect in the COVID-19 pandemic. Vaccines
540	(Basel). 2020;8(2):236. doi:10.3390/vaccines8020236
541	
542	[31] Brown CC, Young SG, Pro GC. COVID-19 vaccination rates vary by community
543	vulnerability: A county-level analysis. Vaccine. 2021;39(31):4245-4249.
544	doi:10.1016/j.vaccine.2021.06.038
545	
546	[32] Chen Y, Ma ZF, Yu D, Jiang Z, Wang B, Yuan L. Geographical distribution of trace
547	elements (selenium, zinc, iron, copper) and case fatality rate of COVID-19: a national
548	analysis across conterminous USA. Environ Geochem Health. 2022;44(12):4423-4436.
549	doi:10.1007/s10653-022-01204-0
550	
551	[33] Weisel O. Vaccination as a social contract: The case of COVID-19 and US political
552	partisanship. Proc Natl Acad Sci U S A. 2021;118(13):e2026745118.
553	doi:10.1073/pnas.2026745118
554	
555	[34] Li T, White LF. Bayesian back-calculation and nowcasting for line list data during
556	the COVID-19 pandemic. PLoS Comput Biol. 2021;17(7):e1009210.
557	doi:10.1371/journal.pcbi.1009210
558	
559	[35] Bergen N, Kirkby K, Fuertes CV, et al. Global state of education-related inequality
560	in COVID-19 vaccine coverage, structural barriers, vaccine hesitancy, and vaccine
561	refusal: findings from the Global COVID-19 Trends and Impact Survey. Lancet Glob
562	Health. 2023;11(2):e207-e217. doi:10.1016/S2214-109X(22)00520-4
563	
564	[36] Chen Y, Zhang L, Li T, Li L. Amplified effect of social vulnerability on health
565	inequality regarding COVID-19 mortality in the USA: the mediating role of vaccination
566	allocation. <i>BMC Public Health</i> . 2022;22(1):2131. doi:10.1186/s12889-022-14592-w
567	

568 569 570 571 572	[37] Buscot MJ, Wotherspoon SS, Magnussen CG, et al. Bayesian hierarchical piecewise regression models: a tool to detect trajectory divergence between groups in long-term observational studies. <i>BMC Med Res Methodol</i> . 2017;17(1). doi:10.1186/s12874-017-0358-9
573 574 575	[38] Li T. <i>The Bayesian Paradigm of Robustness Indices of Causal Inferences</i> . Michigan State University; 2018.
576 577 578	[39] Li T, Frank K. The probability of a robust inference for internal validity. <i>Sociol Methods Res.</i> 2022;51(4):1947-1968. doi:10.1177/0049124120914922
579 580 581	[40] Li T, Frank KA. The probability of a robust inference for internal validity and its applications in regression models. <i>arXiv [statME]</i> . Published online 2020. <u>http://arxiv.org/abs/2005.12784</u>
582 583 584 585	[41] Li T. On the probability of invalidating a causal inference due to limited external validity. <i>arXiv [statME]</i> . Published online 2022. <u>http://arxiv.org/abs/2206.08649</u>
586	
587	
588	
589	
590	
591	
592	
593	
594	